Prime Medicine (PRME) Consolidated Net Income (2021 - 2026)

Prime Medicine (PRME) has 6 years of Consolidated Net Income data on file, last reported at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 4.35% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at -$202.6 million (changed 0.28% YoY), and the FY2025 full-year result was -$204.2 million, down 4.25% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$49.6 million, down from -$47.5 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$23.8 million in Q1 2022 and bottomed at -$65.6 million in Q4 2023.
• The 5-year median for Consolidated Net Income is -$47.5 million (2025), against an average of -$45.3 million.
• Peak annual rise in Consolidated Net Income reached 37.54% in 2022, while the deepest fall reached 78.83% in 2022.
• A 5-year view of Consolidated Net Income shows it stood at -$39.3 million in 2022, then sank by 67.1% to -$65.6 million in 2023, then jumped by 35.6% to -$42.3 million in 2024, then dropped by 12.42% to -$47.5 million in 2025, then retreated by 4.44% to -$49.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$49.6 million (Q1 2026), -$47.5 million (Q4 2025), and -$52.8 million (Q3 2025), per Business Quant data.

Peer Comparison